• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Voyager Therapeutics Inc.

    4/2/25 4:11:47 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VYGR alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0002015616
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Voyager Therapeutics, Inc.
    SEC File Number
    001-37625
    Address of Issuer
    75 HAYDEN AVENUE
    LEXINGTON
    MASSACHUSETTS
    02421
    Phone
    857-259-5340
    Name of Person for Whose Account the Securities are To Be Sold
    Ferguson Toby
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    1008634624.235520688504/02/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common04/01/2025Restricted Stock VestingIssuerCheckbox not checked1008604/01/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
    Date of Notice
    04/02/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Ryan Riviere, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Toby A. Ferguson

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $VYGR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VYGR

    DatePrice TargetRatingAnalyst
    1/10/2025Overweight
    Cantor Fitzgerald
    12/2/2024$12.00Buy
    Citigroup
    11/29/2024$7.00 → $11.00Outperform
    Wedbush
    10/16/2024$15.00Outperform
    Leerink Partners
    3/26/2024$22.00Buy
    Guggenheim
    3/19/2024$30.00Buy
    H.C. Wainwright
    3/7/2024$16.00Buy
    Citigroup
    1/2/2024$14.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $VYGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

      - Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer's di

      3/31/25 7:00:47 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

      - Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer's patients expected H2 2026 - LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2024 financial and operating results. "Over the past year, Voyager has significantly advanced our two wholly-

      3/11/25 4:01:00 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

      LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.

      3/4/25 7:00:00 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Ferguson Toby sold $34,595 worth of shares (10,086 units at $3.43), decreasing direct ownership by 6% to 157,914 units (SEC Form 4)

      4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

      4/4/25 4:10:01 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Sandrock Alfred sold $37,336 worth of shares (10,885 units at $3.43), decreasing direct ownership by 2% to 430,931 units (SEC Form 4)

      4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

      4/4/25 4:08:51 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Carter Todd Alfred sold $14,079 worth of shares (3,305 units at $4.26) and was granted 46,000 shares, increasing direct ownership by 53% to 123,718 units (SEC Form 4)

      4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

      2/24/25 4:21:45 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

      SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

      11/14/24 6:13:11 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

      SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

      11/14/24 5:12:26 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

      SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

      8/7/24 4:10:26 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Voyager Therapeutics Inc.

      10-Q - Voyager Therapeutics, Inc. (0001640266) (Filer)

      5/6/25 4:02:24 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Voyager Therapeutics, Inc. (0001640266) (Filer)

      5/6/25 4:01:12 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Voyager Therapeutics Inc.

      DEFA14A - Voyager Therapeutics, Inc. (0001640266) (Filer)

      4/23/25 4:02:12 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

      LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc. "Voyager has built a strong financial position from which to advance our clinical-stage and emerging pipeline of neurothe

      6/13/24 7:00:00 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NorthStar Appoints Peter Pfreundschuh to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

      4/15/24 9:00:00 AM ET
      $FREQ
      $URGN
      $VYGR
      $IMMU
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

      LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson is a skilled and experienced healthcare executive with a proven record in advancing portfolios of novel therapies across diverse indications in central nervous system (CNS), neuromuscular, and rare diseases. He most recently served as Vice President, Head of Neuromuscular Development Unit at Biogen, Inc. "Voyager is advancing rapidly toward the clinic, with one IND filing targeted each year through

      3/13/24 7:00:00 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    Financials

    Live finance-specific insights

    See more
    • Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

      - Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer's di

      3/31/25 7:00:47 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

      - Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer's patients expected H2 2026 - LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2024 financial and operating results. "Over the past year, Voyager has significantly advanced our two wholly-

      3/11/25 4:01:00 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

      LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.

      3/4/25 7:00:00 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Voyager Therapeutics

      Cantor Fitzgerald initiated coverage of Voyager Therapeutics with a rating of Overweight

      1/10/25 9:15:32 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Citigroup initiated coverage on Voyager Therapeutics with a new price target

      Citigroup initiated coverage of Voyager Therapeutics with a rating of Buy and set a new price target of $12.00

      12/2/24 7:04:18 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush resumed coverage on Voyager Therapeutics with a new price target

      Wedbush resumed coverage of Voyager Therapeutics with a rating of Outperform and set a new price target of $11.00 from $7.00 previously

      11/29/24 7:27:18 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care